AU-314 is under clinical development by Aucentra Therapeutics and currently in Phase II for Uterine Cancer. According to GlobalData, Phase II drugs for Uterine Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AU-314’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AU-314 overview

AU-314 is under development for the treatment of solid tumors including metastatic brain tumor, high grade glioma, recurrent glioblastoma multiforme, cervical, colon, pancreatic and uterine cancers, lung cancer, ovarian, colorectal, liver and breast cancer. It is administered through oral route in the form of capsule. It targets cyclin dependent kinase 4 and 6 (CDK4 and CDK6).

Aucentra Therapeutics overview

Aucentra Therapeutics is an Australian developer of targeted cancer therapeutics. It carries out pre-clinical drug development, drug discovery and research and development activities.

For a complete picture of AU-314’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.